Home » Stocks » MNKKQ

Mallinckrodt PLC (MNKKQ)

Oct 13, 2020 - MNK was delisted due to bankruptcy and now trades as MNKKQ
Stock Price: $0.2250 USD -0.0149 (-6.21%)
Updated Jan 21, 2021 3:55 PM EST - Market closed
Market Cap 19.45M
Revenue (ttm) 2.34B
Net Income (ttm) -1.95B
Shares Out 84.60M
EPS (ttm) -23.17
PE Ratio n/a
Forward PE 0.45
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $0.2250
Previous Close $0.2399
Change ($) -0.0149
Change (%) -6.21%
Day's Open 0.2400
Day's Range 0.2200 - 0.2400
Day's Volume 1,260,864
52-Week Range 0.0652 - 0.469

News

Hide News
  • All
  • Videos
  • Press Releases
PRNewsWire - 6 days ago

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their ca...

Zacks Investment Research - 1 month ago

Top Ranked Value Stocks to Buy for December 21st

Other stocks mentioned: DAC, ELVT
Zacks Investment Research - 1 month ago

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th

Other stocks mentioned: USB, WSBF
PRNewsWire - 2 months ago

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patie...

PRNewsWire - 2 months ago

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipress...

PRNewsWire - 2 months ago

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In ...

PRNewsWire - 2 months ago

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adult...

Business Wire - 3 months ago

ROCKFORD, Ill.--(BUSINESS WIRE)--In April 2017, Rockford sued Mallinckrodt and Express Scripts for antitrust violations. Rockford's lawsuit seeks to return more than $10 billion...

PRNewsWire - 3 months ago

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaw...

The Motley Fool - 3 months ago

Here's what you should know

Market Watch - 3 months ago

Shares of Mallinckrodt Plc tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged...

CNN Business - 3 months ago

Mallinckrodt Pharmaceuticals, facing billions of dollars in legal costs over its role in the nation's opiod crisis, filed for bankruptcy early Monday.

Benzinga - 3 months ago

Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations a...

Reuters - 3 months ago

Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying highe...

PRNewsWire - 3 months ago

DUBLIN, Oct. 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankru...

The Motley Fool - 3 months ago

A House committee has issued detailed reports about some of their drug price increases.

Other stocks mentioned: AMGN, MNK, NVS
Seeking Alpha - 3 months ago

Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.

Zacks Investment Research - 4 months ago

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

PRNewsWire - 4 months ago

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Zacks Investment Research - 4 months ago

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

The Motley Fool - 4 months ago

The proposed law now goes to Gov. Gavin Newsom for his signature.

Other stocks mentioned: MNK, TEVA
PRNewsWire - 4 months ago

ST. LOUIS, Aug. 24, 2020 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been recognized ...

Seeking Alpha - 5 months ago

Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma

PRNewsWire - 5 months ago

STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Zacks Investment Research - 5 months ago

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Seeking Alpha - 5 months ago

Mallinckrodt plc (MNK) CEO Mark Trudeau on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Market Watch - 5 months ago

Shares of Mallinckrodt PLC MNK, -23.00% plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported a...

Benzinga - 5 months ago

Shares of Mallinckrodt (NYSE:MNK) decreased 24% in pre-market trading after the company reported Q2 results.

Market Watch - 5 months ago

Shares of Mallinckrodt PLC MNK, +1.34% rose 0.9% in premrket trading Tuesday, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat ex...

PRNewsWire - 5 months ago

DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a declin...

Zacks Investment Research - 5 months ago

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 5 months ago

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

PRNewsWire - 6 months ago

DUBLIN, July 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. F...

PRNewsWire - 6 months ago

STAINES-UPON-THAMES, United Kingdom, July 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earn...

Zacks Investment Research - 6 months ago

Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.

PRNewsWire - 7 months ago

STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase...

PRNewsWire - 7 months ago

STAINES-UPON-THAMES, United Kingdom, June 11, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical char...

Zacks Investment Research - 7 months ago

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

PRNewsWire - 7 months ago

STAINES-UPON-THAMES, United Kingdom, June 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has...

Zacks Investment Research - 7 months ago

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 7 months ago

STAINES-UPON-THAMES, United Kingdom, June 1, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. Dis...

The Motley Fool - 7 months ago

Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.

Other stocks mentioned: MNK, TEVA
Market Watch - 8 months ago

Shares of Mallinckrodt PLC MNK, -5.97% sank 6.7% in afternoon trading Tuesday, after J.P.

The Motley Fool - 8 months ago

Indiscriminate sell-offs can sometimes lead to opportunities the crowds have missed. Here are three stocks that fit the criteria.

Other stocks mentioned: CGC, MNK, TVTY
Zacks Investment Research - 8 months ago

Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.

The Motley Fool - 8 months ago

Investors were disappointed by the company's Q1 results and the prospects of continued challenges from the COVID-19 pandemic.

About MNKKQ

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesi... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1867
CEO
Mark Trudeau
Employees
3,400
Stock Exchange
OTCMKTS
Ticker Symbol
MNKKQ
Full Company Profile

Financial Performance

In 2019, Mallinckrodt's revenue was $3.16 billion, a decrease of -1.65% compared to the previous year's $3.22 billion. Losses were -$996.50 million, -72.37% less than in 2018.

Financial Statements